Published in J Am Soc Nephrol on February 07, 2007
Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol (2011) 3.68
Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol (2009) 2.12
Posttranslational modification of the AU-rich element binding protein HuR by protein kinase Cdelta elicits angiotensin II-induced stabilization and nuclear export of cyclooxygenase 2 mRNA. Mol Cell Biol (2008) 1.75
Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr Nephrol (2008) 1.29
The angiotensin II-AT1 receptor stimulates reactive oxygen species within the cell nucleus. Biochem Biophys Res Commun (2009) 1.19
Angiotensin type 1 receptor modulates macrophage polarization and renal injury in obesity. Am J Physiol Renal Physiol (2011) 1.13
Endoplasmic reticulum stress implicated in the development of renal fibrosis. Mol Med (2011) 1.09
Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev (2012) 1.07
Angiotensin II induces renal plasminogen activator inhibitor-1 and cyclooxygenase-2 expression post-transcriptionally via activation of the mRNA-stabilizing factor human-antigen R. Am J Pathol (2009) 1.05
Renin-angiotensin system blockade is renoprotective in immune complex-mediated glomerulonephritis. J Am Soc Nephrol (2008) 0.97
Losartan chemistry and its effects via AT1 mechanisms in the kidney. Curr Med Chem (2009) 0.85
Effects of candesartan in hypertensive patients with type 2 diabetes mellitus on inflammatory parameters and their relationship to pulse pressure. Cardiovasc Diabetol (2012) 0.79
Urinary concentration of monocyte chemoattractant protein-1 in idiopathic glomerulonephritis: a long-term follow-up study. PLoS One (2014) 0.78
Differential renal effects of candesartan at high and ultra-high doses in diabetic mice-potential role of the ACE2/AT2R/Mas axis. Biosci Rep (2016) 0.77
Computational drug repositioning for peripheral arterial disease: prediction of anti-inflammatory and pro-angiogenic therapeutics. Front Pharmacol (2015) 0.76
Resveratrol ameliorates renal injury in spontaneously hypertensive rats by inhibiting renal micro-inflammation. Biosci Rep (2016) 0.76
Renoprotective effects of angiotensin receptor blocker and stem cells in acute kidney injury: Involvement of inflammatory and apoptotic markers. Exp Biol Med (Maywood) (2015) 0.75
Renal Artery Stenosis: New Findings from the CORAL Trial. Curr Cardiol Rep (2017) 0.75
Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med (2013) 8.91
A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int (2010) 2.32
Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade. Kidney Int (2008) 1.62
P2X7 receptors mediate deleterious renal epithelial-fibroblast cross talk. Am J Physiol Renal Physiol (2010) 1.57
Hepatocyte growth factor suppresses proinflammatory NFkappaB activation through GSK3beta inactivation in renal tubular epithelial cells. J Biol Chem (2008) 1.42
The Cardiovascular Outcomes with Renal Atherosclerotic Lesions (CORAL) study: rationale and methods. J Vasc Interv Radiol (2005) 1.28
Delayed administration of a single dose of lithium promotes recovery from AKI. J Am Soc Nephrol (2014) 1.28
Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis. J Am Soc Nephrol (2012) 1.19
Hepatocyte growth factor ameliorates renal interstitial inflammation in rat remnant kidney by modulating tubular expression of macrophage chemoattractant protein-1 and RANTES. J Am Soc Nephrol (2004) 1.15
Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for early acute kidney injury. Crit Care Clin (2011) 1.15
Anti-inflammatory effect of hepatocyte growth factor in chronic kidney disease: targeting the inflamed vascular endothelium. J Am Soc Nephrol (2006) 1.14
Activation of PI3K-Akt-GSK3beta pathway mediates hepatocyte growth factor inhibition of RANTES expression in renal tubular epithelial cells. Biochem Biophys Res Commun (2005) 1.02
Sustained activation of EGFR triggers renal fibrogenesis after acute kidney injury. Am J Pathol (2013) 1.01
Evaluation of a recombinant multiepitope peptide for serodiagnosis of Toxoplasma gondii infection. Clin Vaccine Immunol (2012) 1.00
Hepatocyte growth factor modulates matrix metalloproteinases and plasminogen activator/plasmin proteolytic pathways in progressive renal interstitial fibrosis. J Am Soc Nephrol (2003) 0.99
Inhibition of glycogen synthase kinase-3β prevents NSAID-induced acute kidney injury. Kidney Int (2012) 0.98
Suicide gene therapy for hepatocellular carcinoma cells by survivin promoter-driven expression of the herpes simplex virus thymidine kinase gene. Oncol Rep (2013) 0.97
Redox-sensitive glycogen synthase kinase 3β-directed control of mitochondrial permeability transition: rheostatic regulation of acute kidney injury. Free Radic Biol Med (2013) 0.89
ERK pathway mediates P2X7 expression and cell death in renal interstitial fibroblasts exposed to necrotic renal epithelial cells. Am J Physiol Renal Physiol (2011) 0.88
Hepatocyte growth factor ameliorates progression of interstitial fibrosis in rats with established renal injury. Kidney Int (2004) 0.88
Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and -independent mechanisms. Kidney Int (2013) 0.88
Transglutaminase-1 protects renal epithelial cells from hydrogen peroxide-induced apoptosis through activation of STAT3 and AKT signaling pathways. Am J Physiol Renal Physiol (2009) 0.87
Conditional ablation of glycogen synthase kinase 3β in postnatal mouse kidney. Lab Invest (2010) 0.87
Transglutaminase-1 regulates renal epithelial cell proliferation through activation of Stat-3. J Biol Chem (2008) 0.85
Direct fibrogenic effects of aldosterone on normotensive kidney: an effect modified by 11β-HSD activity. Am J Physiol Renal Physiol (2010) 0.85
Suramin alleviates glomerular injury and inflammation in the remnant kidney. PLoS One (2012) 0.85
Pharmacological targeting of GSK3β confers protection against podocytopathy and proteinuria by desensitizing mitochondrial permeability transition. Br J Pharmacol (2014) 0.83
Inhibiting nonmuscle myosin II impedes inflammatory infiltration and ameliorates progressive renal disease. Lab Invest (2010) 0.81
The mechanism of atopic march may be the 'social' event of cells and molecules (Review). Int J Mol Med (2010) 0.80
Aldosterone-induced fibrosis in the kidney: questions and controversies. Am J Kidney Dis (2011) 0.79
Distinct roles of two alternative splice variants of matrilin-2 in protein oligomerization and proteolysis. Mol Med Rep (2012) 0.77
Inhibitory effect of biosynthetic nanoscale peptide Melittin on hepatocellular carcinoma, driven by survivin promoter. J Biomed Nanotechnol (2014) 0.77
Adrenalectomy amplifies aldosterone induced injury in cardiovascular tissue: an effect attenuated by adrenally derived steroids. Steroids (2012) 0.76
Hepatocyte growth factor induces an endothelin-mediated decline in glomerular filtration rate. Am J Physiol Renal Physiol (2005) 0.76
Stenting for renal-artery stenosis. N Engl J Med (2014) 0.75
Targeting and eradicating hepatic cancer cells with a cancer-specific vector carrying the Buforin II gene. Cancer Biother Radiopharm (2013) 0.75
Gene therapy with biosynthetic nanoscale peptide Cecropin A driven by the survivin promoter for hepatocarcinoma cells. J Biomed Nanotechnol (2014) 0.75
Lei-Shi Li: a giant in international nephrology. Kidney Int (2010) 0.75
[Acquired mutation of type II transforming growth factor-beta receptor gene in glomerulosclerosis]. Zhonghua Yi Xue Za Zhi (2002) 0.75
Medical Neighborhood Model for the Care of Chronic Kidney Disease Patients. Am J Nephrol (2016) 0.75